Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Iron toxicity - Its effect on the bone marrow.

Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, Loscocco F, Visani G, Cianciulli P.

Blood Rev. 2018 Nov;32(6):473-479. doi: 10.1016/j.blre.2018.04.004. Epub 2018 Apr 13. Review.

PMID:
29699840
2.

Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.

Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S.

Leuk Res. 2017 Nov;62:108-115. doi: 10.1016/j.leukres.2017.10.001. Epub 2017 Oct 5. Review.

PMID:
29054020
3.

Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry.

Borgna-Pignatti C, Garani MC, Forni GL, Cappellini MD, Cassinerio E, Fidone C, Spadola V, Maggio A, Restivo Pantalone G, Piga A, Longo F, Gamberini MR, Ricchi P, Costantini S, D'Ascola D, Cianciulli P, Lai ME, Carta MP, Ciancio A, Cavalli P, Putti MC, Barella S, Amendola G, Campisi S, Capra M, Caruso V, Colletta G, Volpato S.

Br J Haematol. 2014 Oct;167(1):121-6. doi: 10.1111/bjh.13009. Epub 2014 Jul 3.

PMID:
24992281
4.

Antibodies reacting with Simian virus 40 mimotopes in serum samples from patients with thalassaemia major.

Borgna-Pignatti C, Mazzoni E, Felletti M, Turlà G, Malaventura C, Cappellini MD, Cianciulli P, Forni GL, Corallini A, Martini F, Tognon M.

Blood Transfus. 2014 Oct;12(4):464-70. doi: 10.2450/2013.0220-13. Epub 2014 Mar 19.

5.

Dark blood versus bright blood T2 acquisition in cardiovascular magnetic resonance (CMR) for thalassaemia major (TM) patients: evaluation of feasibility, reproducibility and image quality.

Liguori C, Di Giampietro I, Pitocco F, De Vivo AE, Schena E, Mortato L, Pirro F, Cianciulli P, Zobel BB.

Eur J Radiol. 2014 Jan;83(1):e8-e14. doi: 10.1016/j.ejrad.2013.10.007. Epub 2013 Oct 19.

PMID:
24238939
6.

Ectopic calcification in β-thalassemia patients is associated with increased oxidative stress and lower MGP carboxylation.

Boraldi F, Garcia-Fernandez M, Paolinelli-Devincenzi C, Annovi G, Schurgers L, Vermeer C, Cianciulli P, Ronchetti I, Quaglino D.

Biochim Biophys Acta. 2013 Dec;1832(12):2077-84. doi: 10.1016/j.bbadis.2013.07.017. Epub 2013 Jul 27.

7.

Relationship between myocardial T2 values and cardiac volumetric and functional parameters in β-thalassemia patients evaluated by cardiac magnetic resonance in association with serum ferritin levels.

Liguori C, Pitocco F, Di Giampietro I, de Vivo AE, Schena E, Cianciulli P, Zobel BB.

Eur J Radiol. 2013 Sep;82(9):e441-7. doi: 10.1016/j.ejrad.2013.03.025. Epub 2013 Apr 29.

PMID:
23639773
8.

Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.

Filosa A, Vitrano A, Rigano P, Calvaruso G, Barone R, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Casale M, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Maggio A.

Blood Cells Mol Dis. 2013 Aug;51(2):85-8. doi: 10.1016/j.bcmd.2013.04.002. Epub 2013 Apr 28.

PMID:
23628348
9.

MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A.

Lulli V, Romania P, Morsilli O, Cianciulli P, Gabbianelli M, Testa U, Giuliani A, Marziali G.

PLoS One. 2013 Apr 4;8(4):e60436. doi: 10.1371/journal.pone.0060436. Print 2013.

10.

Fibroblast involvement in soft connective tissue calcification.

Ronchetti I, Boraldi F, Annovi G, Cianciulli P, Quaglino D.

Front Genet. 2013 Mar 5;4:22. doi: 10.3389/fgene.2013.00022. eCollection 2013.

11.

Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac death.

Maggio A, Vitrano A, Calvaruso G, Barone R, Rigano P, Mancuso L, Cuccia L, Capra M, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C, Campisi S, Cianciulli P, Elefteriou A, Angastiniotis M, Hamza H, Telfer P, Walker JM, Phrommintikul A, Chattipakorn N.

Blood Cells Mol Dis. 2013 Apr;50(4):241-6. doi: 10.1016/j.bcmd.2012.12.002. Epub 2013 Jan 20.

PMID:
23337255
12.

Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.

Pepe A, Meloni A, Rossi G, Cuccia L, D'Ascola GD, Santodirocco M, Cianciulli P, Caruso V, Romeo MA, Filosa A, Pitrolo L, Putti MC, Peluso A, Campisi S, Missere M, Midiri M, Gulino L, Positano V, Lombardi M, Ricchi P.

J Cardiovasc Magn Reson. 2013 Jan 16;15:1. doi: 10.1186/1532-429X-15-1.

13.

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.

Maggio A, Vitrano A, Lucania G, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Di Maggio R, Calvaruso G, Pantalone GR, Rigano P.

Am J Hematol. 2012 Jul;87(7):732-3. doi: 10.1002/ajh.23219. Epub 2012 May 24.

14.

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.

Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassarà F, Harmatz P, Wood J, Gluud C.

Blood Cells Mol Dis. 2011 Oct 15;47(3):166-75. doi: 10.1016/j.bcmd.2011.07.002. Epub 2011 Aug 16. Review.

PMID:
21843958
15.

Malignancies in β-thalassemia patients: first description of two cases of thyroid cancer and review of the literature.

Poggi M, Sorrentino F, Pascucci C, Monti S, Lauri C, Bisogni V, Toscano V, Cianciulli P.

Hemoglobin. 2011;35(4):439-46. doi: 10.3109/03630269.2011.588355. Review.

PMID:
21797713
16.

The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients.

Ceci A, Mangiarini L, Felisi M, Bartoloni F, Ciancio A, Capra M, D'Ascola D, Cianciulli P, Filosa A.

Anemia. 2011;2011:435683. doi: 10.1155/2011/435683. Epub 2011 Jun 5.

17.

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.

Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.

Hemoglobin. 2011;35(3):206-16. doi: 10.3109/03630269.2011.570674.

PMID:
21599433
18.

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A.

Haematologica. 2011 Jan;96(1):41-7. doi: 10.3324/haematol.2009.019042. Epub 2010 Sep 30.

19.

Renal complications in transfusion-dependent beta thalassaemia.

Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD.

Blood Rev. 2010 Nov;24(6):239-44. doi: 10.1016/j.blre.2010.08.004. Epub 2010 Sep 20. Review.

PMID:
20850917
20.

Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.

Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.

Blood Cells Mol Dis. 2010 Aug 15;45(2):136-9. doi: 10.1016/j.bcmd.2010.05.005. Epub 2010 Jun 17.

PMID:
20678715
21.

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, Kattamis A, Prossamariti L, Filosa A, Rund D, Gamberini MR, Cianciulli P, De Montalembert M, Gagliardotto F, Foster G, Grangè JD, Cassarà F, Iacono A, Cappellini MD, Brittenham GM, Prati D, Pietrangelo A, Craxì A, Maggio A; Italian Society for the Study of Thalassemia and Haemoglobinopathies; Italian Association for the Study of the Liver.

Blood. 2010 Oct 21;116(16):2875-83. doi: 10.1182/blood-2009-11-248724. Epub 2010 Jun 15.

PMID:
20551378
22.

[Laparoscopic splenectomy in haematological diseases: short- and medium-term results in thirty initial cases].

Carlini M, Giovannini C, Castaldi F, Cianciulli P, Sorrentino F, Mercadante E.

Chir Ital. 2009 Jul-Aug;61(4):427-33. Italian.

PMID:
19845264
23.

Safety of cardiovascular magnetic resonance gadolinium chelates contrast agents in patients with hemoglobinopathies.

Meloni A, Favilli B, Positano V, Cianciulli P, Filosa A, Quarta A, D'Ascola D, Restaino G, Lombardi M, Pepe A.

Haematologica. 2009 Nov;94(11):1625-7. doi: 10.3324/haematol.2009.010181. Epub 2009 Aug 27. No abstract available.

24.

Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron.

Ramazzotti A, Pepe A, Positano V, Rossi G, De Marchi D, Brizi MG, Luciani A, Midiri M, Sallustio G, Valeri G, Caruso V, Centra M, Cianciulli P, De Sanctis V, Maggio A, Lombardi M.

J Magn Reson Imaging. 2009 Jul;30(1):62-8. doi: 10.1002/jmri.21781.

PMID:
19557847
25.

Giant symptomatic myelolipoma of the right adrenal gland: a case report.

Dell'Avanzato R, Castaldi F, Giovannini C, Mercadante E, Cianciulli P, Carlini M.

Chir Ital. 2009 Mar-Apr;61(2):231-6.

PMID:
19536999
26.

Pain syndromes in sickle cell disease: an update.

Niscola P, Sorrentino F, Scaramucci L, de Fabritiis P, Cianciulli P.

Pain Med. 2009 Apr;10(3):470-80. doi: 10.1111/j.1526-4637.2009.00601.x. Review.

PMID:
19416438
27.

Treatment of iron overload in thalassemia.

Cianciulli P.

Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:208-13. Review.

PMID:
19337180
28.

Hereditary spherocytosis and elliptocytosis associated with prosthetic heart valve replacement: rheological study of erythrocyte modifications.

Caprari P, Tarzia A, Mojoli G, Cianciulli P, Mannella E, Martorana MC.

Int J Hematol. 2009 Apr;89(3):285-293. doi: 10.1007/s12185-009-0270-0. Epub 2009 Mar 24.

PMID:
19308658
29.

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.

Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.

Br J Haematol. 2009 Apr;145(2):245-54. doi: 10.1111/j.1365-2141.2009.07609.x. Epub 2009 Feb 19.

PMID:
19236376
30.

Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.

Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.

Blood Cells Mol Dis. 2009 May-Jun;42(3):247-51. doi: 10.1016/j.bcmd.2009.01.002. Epub 2009 Feb 23.

PMID:
19233692
31.

Iron chelation therapy in thalassemia syndromes.

Cianciulli P.

Mediterr J Hematol Infect Dis. 2009 Dec 29;1(1):e2009034. doi: 10.4084/MJHID.2009.034.

32.

Improved T2* assessment in liver iron overload by magnetic resonance imaging.

Positano V, Salani B, Pepe A, Santarelli MF, De Marchi D, Ramazzotti A, Favilli B, Cracolici E, Midiri M, Cianciulli P, Lombardi M, Landini L.

Magn Reson Imaging. 2009 Feb;27(2):188-97. doi: 10.1016/j.mri.2008.06.004. Epub 2008 Jul 30.

PMID:
18667287
33.

Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study.

Scalone L, Mantovani LG, Krol M, Rofail D, Ravera S, Bisconte MG, Borgna-Pignatti C, Borsellino Z, Cianciulli P, Gallisai D, Prossomariti L, Stefàno I, Cappellini MD.

Curr Med Res Opin. 2008 Jul;24(7):1905-17. doi: 10.1185/03007990802160834 . Epub 2008 May 27.

PMID:
18507891
34.

Guideline recommendations for heart complications in thalassemia major.

Cogliandro T, Derchi G, Mancuso L, Mayer MC, Pannone B, Pepe A, Pili M, Bina P, Cianciulli P, De Sanctis V, Maggio A; Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE).

J Cardiovasc Med (Hagerstown). 2008 May;9(5):515-25. doi: 10.2459/JCM.0b013e3282f20847.

PMID:
18404006
35.

Standardized T2* map of a normal human heart to correct T2* segmental artefacts; myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patients.

Ramazzotti A, Pepe A, Positano V, Scattini B, Santarelli MF, Landini L, De Marchi D, Keilberg P, Derchi G, Formisano F, Pili M, Lai ME, Forni G, Filosa A, Prossomariti L, Capra M, Pitrolo L, Borgna-Pignatti C, Cianciulli P, Maggio A, Lombardi M.

Hemoglobin. 2008;32(1-2):97-107. doi: 10.1080/03630260701879514.

PMID:
18274987
36.

Anemia in beta-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression.

Camberlein E, Zanninelli G, Détivaud L, Lizzi AR, Sorrentino F, Vacquer S, Troadec MB, Angelucci E, Abgueguen E, Loréal O, Cianciulli P, Lai ME, Brissot P.

Haematologica. 2008 Jan;93(1):111-5. doi: 10.3324/haematol.11656.

37.

Effective erythropoiesis and HbF reactivation induced by kit ligand in beta-thalassemia.

Gabbianelli M, Morsilli O, Massa A, Pasquini L, Cianciulli P, Testa U, Peschle C.

Blood. 2008 Jan 1;111(1):421-9. Epub 2007 Oct 19.

PMID:
17951528
38.

Sickle cell anaemia: haemorheological aspects.

Martorana MC, Mojoli G, Cianciulli P, Tarzia A, Mannella E, Caprari P.

Ann Ist Super Sanita. 2007;43(2):164-70.

39.

Neuroacanthocytosis associated with a defect of the 4.1R membrane protein.

Orlacchio A, Calabresi P, Rum A, Tarzia A, Salvati AM, Kawarai T, Stefani A, Pisani A, Bernardi G, Cianciulli P, Caprari P.

BMC Neurol. 2007 Feb 13;7:4.

40.

Risk factors for death in patients with beta-thalassemia major: results of a case-control study.

Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, Del Vecchio GC, Magnano C, Meo A, Maggio A.

Haematologica. 2006 Oct;91(10):1420-1. Epub 2006 Sep 7.

41.

Acanthocytosis as a predisposing factor for non-ketotic hyperglycaemia induced chorea-ballism.

Pisani A, Diomedi M, Rum A, Cianciulli P, Floris R, Orlacchio A, Bernardi G, Calabresi P.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1717-9.

42.

LPI-labile plasma iron in iron overload.

Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P.

Best Pract Res Clin Haematol. 2005 Jun;18(2):277-87. Review.

PMID:
15737890
43.

Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases.

Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G, Forni GL, Magnano C, Meo A, Gramignoli R, Rebulla P, Fiorelli G, Cappellini MD; Cooleycare Cooperative Group.

Haematologica. 2004 Oct;89(10):1179-86.

44.

Hepatocellular carcinoma in the thalassaemia syndromes.

Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG.

Br J Haematol. 2004 Jan;124(1):114-7.

PMID:
14675416
45.

Acquired Pseudoxanthoma elasticum-like syndrome in beta-thalassaemia patients.

Hamlin N, Beck K, Bacchelli B, Cianciulli P, Pasquali-Ronchetti I, Le Saux O.

Br J Haematol. 2003 Sep;122(5):852-4.

PMID:
12930400
46.

Cardiovascular involvement in thalassaemic patients with pseudoxanthoma elasticum-like skin lesions: a long-term follow-up study.

Cianciulli P, Sorrentino F, Maffei L, Amadori S, Cappabianca MP, Foglietta E, Carnevali E, Pasquali-Ronchetti I.

Eur J Clin Invest. 2002 Sep;32(9):700-6.

PMID:
12486871
47.

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rizzo A, Midiri M.

Blood Cells Mol Dis. 2002 Mar-Apr;28(2):196-208.

PMID:
12064916
48.

Identification of G6PD Mediterranean mutation by amplification refractory mutation system.

Maffi D, Pasquino MT, Caprari P, Caforio MP, Cianciulli P, Sorrentino F, Cappabianca MP, Salvati AM.

Clin Chim Acta. 2002 Jul;321(1-2):43-7.

PMID:
12031591
49.

Thrombophilia in thalassemia major patients: analysis of genetic predisposing factors.

Iolascon A, Giordano P, Storelli S, Li HH, Coppola B, Piga A, Fantola E, Forni G, Cianciulli P, Perrotta S, Magnano C, Maggio A, Mangiagli A, Devoto M.

Haematologica. 2001 Oct;86(10):1112-3. No abstract available.

50.

6-Phosphogluconate dehydrogenase deficiency in an Italian family.

Caprari P, Caforio MP, Cianciulli P, Maffi D, Pasquino MT, Tarzia A, Amadori S, Salvati AM.

Ann Hematol. 2001 Jan;80(1):41-4.

PMID:
11233775

Supplemental Content

Loading ...
Support Center